Addyi Geriatric (65+) Caregiver Administration Guidance

What Caregivers Must Know Before the First Dose

Flibanserin carries a boxed warning for severe hypotension and syncope, risks that are substantially higher in older adults because of age-related changes in baroreceptor sensitivity, polypharmacy burden, and reduced hepatic CYP3A4 activity [1]. The FDA approved flibanserin in August 2015 under a Risk Evaluation and Mitigation Strategy (REMS) that requires all prescribers and dispensing pharmacies to complete training before the drug is prescribed or filled [2].

Understanding the REMS Requirement

The Addyi REMS mandates that patients (or their authorized caregivers) sign a Patient-Provider Agreement Form acknowledging the alcohol restriction and syncope risk before the first prescription is dispensed [2]. Caregivers should retain a copy of this form. If the pharmacy did not provide it, contact the prescribing clinician before administering any dose.

Why Older Age Changes the Risk Profile

Physiological aging reduces first-pass hepatic metabolism and lowers plasma protein binding capacity, both of which can raise effective flibanserin exposure above the levels studied in trials [3]. The key VIOLET and DAISY trials that supported FDA approval enrolled predominantly premenopausal women with a mean age of approximately 36 years; patients over 65 were excluded [4]. Every caregiver decision for a geriatric patient is therefore based on extrapolation, not direct trial evidence.

Confirming the Correct Indication

Flibanserin is labeled only for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [1]. Its use in postmenopausal women and in patients older than 65 is off-label. The prescribing clinician should have documented the specific HSDD diagnosis, confirmed that distress is present, and ruled out relationship factors, mood disorders, and medication-induced low desire before initiating therapy [5].

Dosing and Administration Protocol for Caregivers

The labeled dose is 100 mg once daily, taken orally at bedtime. No lower starting dose is specified in the FDA prescribing information for geriatric patients [1]. Some clinicians informally recommend beginning at 50 mg (one-half tablet) in adults over 65 to assess tolerability, but this is not an FDA-approved practice. Discuss any dose modification with the prescribing clinician in writing before changing the regimen.

Bedtime-Only Administration Is Non-Negotiable

Giving flibanserin in the morning or afternoon markedly increases the chance of hypotension, dizziness, and falls during waking hours [1]. Bedtime administration allows the peak plasma concentration, which occurs approximately 45 minutes to 2 hours after ingestion, to coincide with sleep [6]. Even so, next-morning sedation is common; caregivers should allow the patient to sit at the edge of the bed for at least 60 seconds before standing.

Step-by-Step Administration Checklist

1. Confirm no alcohol has been consumed in the past 2 hours and none will be consumed after the dose.
2. Verify no new prescriptions or over-the-counter medications (especially antifungals, antihistamines, or antibiotics) were started that day.
3. Administer the 100 mg tablet with a small amount of water, food does not substantially alter absorption and may be offered if preferred [1].
4. Ensure the patient moves directly to bed after swallowing the tablet.
5. Document the time of administration in the caregiver log.
6. Check on the patient before she stands the following morning; confirm she is alert and not dizzy before assisting with mobilization.

What to Do If a Dose Is Missed

Skip the missed dose entirely. Do not double up the next evening. Resuming the usual bedtime dose the following night is appropriate [1]. There is no clinically meaningful penalty to a single missed dose given flibanserin's half-life of approximately 11 hours [6].

Alcohol: The Highest-Priority Safety Rule

Alcohol co-ingestion with flibanserin produces clinically significant additive CNS and cardiovascular depression. In a dedicated drug-alcohol interaction study cited in the prescribing information, five of 25 subjects experienced symptomatic hypotension or syncope when alcohol was combined with flibanserin [1]. That is a 20% event rate in a controlled setting with healthy subjects, not elderly patients with baseline cardiovascular vulnerability.

Defining "Complete Avoidance"

The FDA label states that patients must abstain from alcohol use while taking flibanserin [1]. For caregivers, this means:

• No wine, beer, spirits, or alcohol-containing cough syrups on any day flibanserin is taken.
• Wine at a dinner event earlier in the day does not make bedtime dosing safe. Skip that night's dose and document the reason.
• Mouthwashes containing ethanol (up to 26% alcohol) should be replaced with alcohol-free alternatives during therapy [7].

Managing Social and Cultural Contexts

Older adults in many cultures use alcohol socially or as part of religious observance. Caregivers should discuss realistic mitigation strategies with the care team. If alcohol abstinence cannot be reliably ensured, the prescribing clinician needs to know, because flibanserin may not be appropriate for that patient [5].

Drug Interactions in Geriatric Patients

Flibanserin is metabolized primarily by CYP3A4 and, to a lesser extent, CYP2C19 [1]. Geriatric patients carry disproportionately high polypharmacy burdens. A 2019 analysis in JAMA Internal Medicine found that 42% of U.S. Adults aged 65 and older take five or more prescription medications simultaneously [8]. Each new drug added to a flibanserin regimen must be screened for CYP3A4 inhibition or CNS additive effects.

Contraindicated CYP3A4 Inhibitors

The FDA label lists the following as contraindicated with flibanserin due to risk of severe hypotension and syncope [1]:

• Azole antifungals: fluconazole, itraconazole, ketoconazole, posaconazole
• Macrolide antibiotics: clarithromycin, telithromycin
• HIV protease inhibitors: ritonavir, saquinavir, nelfinavir, lopinavir
• Non-dihydropyridine calcium channel blockers: diltiazem, verapamil
• Grapefruit juice (consume none while on therapy)

A caregiver who notices any of these agents added to the medication list should hold the flibanserin dose and contact the prescribing clinician the same day.

CNS Depressants That Compound Sedation

The following drug classes, all common in geriatric patients, can add to flibanserin-related CNS depression and increase fall risk [1] [9]:

• Benzodiazepines (alprazolam, lorazepam, temazepam)
• Z-drugs (zolpidem, eszopiclone)
• Sedating antihistamines (diphenhydramine, hydroxyzine)
• Opioid analgesics
• Antipsychotics with sedative properties (quetiapine, olanzapine)
• Tricyclic antidepressants

Caregivers should bring a complete, current medication list to every clinical visit and ask specifically whether each sedating agent is still indicated given the addition of flibanserin.

Moderate CYP3A4 Inhibitors Requiring Caution

Fluoxetine, ciprofloxacin, and ranitidine are moderate CYP3A4 inhibitors that may raise flibanserin exposure without reaching the threshold for absolute contraindication [1]. The prescribing clinician should be aware of any of these in the regimen and may elect to monitor more frequently for dizziness or hypotension.

Fall Risk Assessment and Prevention

Falls are the leading cause of injury death in U.S. Adults aged 65 and older; the CDC reports approximately 36 million falls annually in this population, resulting in more than 32,000 deaths per year [10]. Flibanserin's hypotensive and sedating effects directly add to this baseline risk.

Environmental Modifications Before Starting Therapy

Before the first dose is given, caregivers should complete the following home safety review:

• Remove loose rugs and floor clutter in the path from bed to bathroom.
• Install grab bars beside the toilet and in the shower if not already present.
• Place a non-slip mat beside the bed.
• Ensure a nightlight or motion-sensing light illuminates the path to the bathroom.
• Move commonly needed items (water glass, phone, glasses) to bedside to reduce the need for nighttime mobility.

Morning Mobilization Protocol

Orthostatic hypotension is the primary fall mechanism with flibanserin. Caregivers should apply a structured orthostatic protocol each morning [11]:

1. Sit with the patient at the edge of the bed for 60 seconds.
2. Check for dizziness or light-headedness verbally.
3. Assist to a standing position slowly, maintaining a physical handhold.
4. Wait 30 additional seconds in standing before releasing support.
5. If systolic blood pressure drops more than 20 mmHg on standing (measured with a home cuff), log the reading and contact the prescribing clinician.

Blood Pressure Monitoring Schedule

Baseline standing and supine blood pressure should be recorded before therapy begins. Recheck at 2 weeks, 4 weeks, and then monthly for the first 6 months. The American Heart Association defines orthostatic hypotension as a sustained reduction in systolic BP of at least 20 mmHg or diastolic BP of at least 10 mmHg within 3 minutes of standing [12].

Monitoring for Efficacy: When to Stop

The FDA prescribing information specifies that flibanserin should be discontinued after 8 weeks if the patient has not reported a meaningful improvement in satisfying sexual events or distress related to low desire [1]. In geriatric patients, who were not enrolled in the key trials, the same 8-week checkpoint applies by extrapolation.

Defining Meaningful Response

The key VIOLET trial (N=1,060) found that women on flibanserin 100 mg reported an increase of approximately 0.5 to 1.0 satisfying sexual events per month above placebo at 24 weeks, alongside reduced distress scores on the Female Sexual Distress Scale-Revised (FSDS-R) [4]. These are modest but statistically significant gains. Caregivers supporting a geriatric patient should help track whether the patient herself reports feeling less distressed about low desire, as that subjective outcome is the primary regulatory endpoint.

Tracking Tools for Caregivers

A simple daily log noting (1) any hypotensive or dizzy episodes, (2) sedation level on waking (scale of 1 to 5), (3) any falls or near-falls, and (4) the patient's own reported distress level (scale of 1 to 10) gives the prescribing clinician actionable data at each follow-up visit. Paper logs are acceptable; a smartphone note or spreadsheet works equally well.

Cognitive and Psychological Considerations

Older adults with HSDD may also carry diagnoses of mild cognitive impairment, depression, or anxiety. Depression and HSDD share overlapping symptom profiles, and several antidepressants (SSRIs, SNRIs) themselves reduce libido, creating a diagnostic overlap that must be sorted before attributing low desire solely to HSDD [5].

Flibanserin and Existing Antidepressant Therapy

Flibanserin is not an antidepressant and should not be substituted for one. SSRIs such as sertraline and escitalopram are weak CYP3A4 inhibitors; they may modestly raise flibanserin plasma levels, though they are not listed as contraindicated [1]. Fluoxetine, a stronger CYP2D6 and CYP3A4 inhibitor, warrants a specific clinical review before co-prescribing [1].

Communicating With a Patient Who Has Mild Cognitive Impairment

Patients with mild cognitive impairment may not reliably self-report dizziness or syncope prodrome. Caregivers in this context become the primary safety monitor. Establish a brief, concrete morning check-in: "Did you feel dizzy when you woke up? Did you feel unsteady?" Document responses. Any affirmative answer warrants a call to the prescribing clinician before the next dose is given.

Special Scenarios in Geriatric Care Settings

Assisted Living and Memory Care Facilities

In a facility setting, medication administration is typically handled by nursing staff, not family caregivers. Ensure the prescribing physician communicates the bedtime-only rule and alcohol restriction directly in the medication administration record (MAR). Verbal handoffs between shifts are insufficient given the severity of the interaction risk. The REMS Patient-Provider Agreement must be on file with the facility pharmacy.

Visiting or Part-Time Caregivers

If a patient lives alone and a caregiver visits only during daytime hours, the caregiver cannot ensure bedtime administration or morning mobilization. In this scenario, a remote check-in protocol (phone or video call at the time of dosing and again the following morning) should be established with the care team before therapy begins.

Hospitalizations and Surgical Procedures

Flibanserin should generally be held during hospitalizations where IV fluids, anesthetics, or opioids will be administered, given compounded hypotension risk. Caregivers should inform every anesthesiologist, hospitalist, and surgeon about the flibanserin prescription. Because the half-life is approximately 11 hours, the drug is largely cleared within 24 to 48 hours of the last dose [6].

Original Clinical Framework for Caregiver Decision-Making

The following stepwise framework was developed by the HealthRX medical team to guide caregivers through the most common decision points encountered during flibanserin therapy in patients aged 65 and older. No single published guideline currently addresses caregiver-specific administration for this population.

Step 1. Pre-dose daily screen (30 seconds) Ask: alcohol today? New medication today? Feeling dizzy now? If any answer is yes, hold dose and document.

Step 2. Administer at bedtime Give tablet with water. Patient moves directly to bed. Log time.

Step 3. Next-morning mobilization screen (2 minutes) Sit at bed edge 60 seconds. Stand with assistance. Check for dizziness. Measure BP if standing BP has previously been low.

Step 4. Weekly efficacy and tolerability review Review caregiver log. Note falls, hypotensive episodes, sedation scores, and patient-reported distress ratings.

Step 5. Eight-week decision point Bring log to prescribing clinician. If no improvement in patient-reported distress or satisfying sexual events, the clinical default per FDA labeling is discontinuation [1].

Regulatory and Legal Context for Caregivers

The Addyi REMS was implemented because post-marketing surveillance and pre-approval trial data showed that the syncope and hypotension risks were not manageable through standard labeling alone [2]. Caregivers who administer flibanserin to a patient who then experiences syncope and injury without following REMS protocols (alcohol avoidance, bedtime dosing, interaction screening) may face questions about standard-of-care adherence in any resulting legal review.

This is not a reason to avoid the drug if it is clinically appropriate. It is a reason to document each administration carefully and to maintain communication with the prescribing clinician whenever safety questions arise. The FDA MedWatch program accepts adverse event reports from caregivers directly at fda.gov/safety/medwatch [13].